

REMARKS


The amendment to the claims is merely to delete improper multiple dependencies and to place the application into better form for examination. Entry of the present amendment and favorable action on the above-identified application are earnestly solicited.

Attached hereto is a marked-up copy of the changes made to the application by this Amendment.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By 
Gerald M. Murphy, Jr., #28,977

P.O. Box 747
Falls Church, VA 22040-0747
(703) 205-8000

GMM/cqc
2815-0159P

Attachment: Version with Markings Showing Changes Made

(Rev. 01/22/01)

VERSION WITH MARKINGS TO SHOW CHANGES MADE

The claims have been amended as follows:

21. (Amended) A pharmaceutical composition comprising a therapeutically effective amount of a chemical compound represented by the general formula I of [claims 1-20]claim 1, or a pharmaceutically-acceptable addition salt thereof, together with at least one pharmaceutically-acceptable carrier or diluent, for the treatment or alleviation of a disease or a disorder or a condition responsive to modulation of SKCa, IKCa and/or BKCa channels.

23. (Amended) Use of a chemical compound represented by the general formula I of [claims 1-20]claim 1, or a pharmaceutically-acceptable addition salt thereof, for the manufacture of a pharmaceutical composition for the treatment or alleviation of a disease or a disorder or a condition of a mammal, including a human, which disease disorder or condition is responsive to modulation of SKCa, IKCa and/or BKCa channels.

24. (Amended) A method of treatment or alleviation of a disease or a condition of a living animal body, including a human, which disorder, disease or condition is responsive to modulation of SKCa, IKCa and/or BKCa channels, comprising the step of administering to such a living animal body, including a human, in need thereof a

therapeutically effective amount of a chemical compound represented by the general formula I of [claims 1 to 20]claim 1, or a pharmaceutically-acceptable addition salt thereof.

TO: 10/15/00